Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG) - Dutton, S; Blazeby, J; Petty, R; Mansoor, W; Thompson, J; Harrison, M; Abbas, H; Dahle-Smith, A; Chatterjee, A; Falk, S; Garcia-Alonso, A; Fyfe, D; et al. (2013)